Communicators

are winners!

More News

07.03.2022
Safety Committee Clears Next Dose - Phase I Clinical Study of RECCE® 327 (1,000mg I.V)
21.02.2022
Final Subjects Dosed in Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
08.02.2022
Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
18.01.2022
Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
10.01.2022
Positive Safety Data from First Cohort of Phase I - Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
15.12.2021
Recce Pharmaceuticals: Patients to be Dosed in Phase I Intravenous Clinical Trial of RECCE® 327
07.12.2021
Recce Pharmaceuticals: Update on Phase I/II Clinical Trial for the Treatment of Burn Wound Infections
25.10.2021
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I Intravenous Clinical Trial of RECCE® 327
30.09.2021
RECCE® 327 Trial Registered in the Australian New Zealand Clinical Trials Registry for Phase I Intravenous Study in Humans
11.08.2021
Recce Pharmaceuticals Receives Entrepreneurs’ Programme Innovation Connections Grant